Related Experiment Videos
Comparison of plain and Gd-DTPA-enhanced MR-imaging in children
P Baierl1, A Mühlsteffen, J Haustein
1Radiologische Klinik und Poliklinik, Klinikum Grosshadern, München, FRG.
Insights
Gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA) contrast enhancement in MRI significantly improves lesion detection and characterization in pediatric patients. This supplementary examination is crucial for diagnosing central nervous system (CNS) tumors and infections when initial MRI is inconclusive.
Area of Science:
- Pediatric Radiology
- Neuroimaging
- Magnetic Resonance Imaging
Background:
- Magnetic Resonance Imaging (MRI) is a key diagnostic tool in pediatric neurology.
- Contrast agents like Gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA) can enhance visualization of central nervous system (CNS) abnormalities.
- The safety and efficacy of Gd-DTPA in pediatric populations require specific evaluation.
Purpose of the Study:
- To evaluate the diagnostic utility of Gd-DTPA enhanced MRI in children and adolescents.
- To assess the impact of Gd-DTPA on detecting and characterizing CNS lesions.
- To determine the safety profile of Gd-DTPA in this age group.
Main Methods:
- 40 children and adolescents (aged 1-16 years) underwent 1.0 T MRI.
- Intravenous administration of Gd-DTPA at 0.1 mmol/kg body weight.
- T1-weighted spin-echo (SE) sequences were employed to assess contrast enhancement.
Main Results:
- No adverse effects were observed following Gd-DTPA administration.
- Lesions were present in 30 patients, with contrast enhancement noted in 20.
- Gd-DTPA enabled detection of lesions missed on plain MRI in 4 cases and aided differentiation of lesion components (edema/necrosis) in 13 patients.
- Age-dependent signal increase observed in vertebral bone marrow, distinct from lesion enhancement.
Conclusions:
- Gd-DTPA enhanced MRI is a safe and valuable supplementary tool in pediatric neuroimaging.
- It improves the detection and characterization of CNS lesions, particularly in suspected tumors or infections.
- Gd-DTPA is recommended when plain MRI is normal or insufficient for definitive diagnosis in pediatric CNS evaluations.
Abstract:
40 children and adolescents (aged 1-16 years) were examined by MRI at 1.0 T. Gd-DTPA was given intravenously at a dose of 0.1 mmol/kg body weight. In all cases T1-weighted SE sequences were used to demonstrate contrast enhancement. No adverse effects were seen. 30 patients had one or more lesions; in 20 patients contrast enhancement was seen. In 4 cases lesions were not observed by plain MRI and could only be detected after Gd-DTPA. In addition, contrast enhancement provided additional information about the differentiation of lesion from edema or necrosis in 13 patients. Normal brain matter did not show any changes in signal intensity. However, an age-dependent signal increase was found in the normal vertebral bone marrow in all children. Gd-DTPA should be used as a supplementary examination whenever a tumor or an infectious disease of the CNS is suspected and plain MRI is normal, or when origin and extent of a lesion cannot be adequately defined with plain MRI.